2-(5-BroMo-2-Methylbenzyl)-5-(4-fluorophenyl)thiophene1030825-20-7

Basic Information:
Chinese Name: 2-(2-methyl-5-bromobenzyl)-5-(4-fluorobenzene)thiophene
Chinese aliases: Cangliflozin intermediate 1
Casagliflozin intermediate (CAR-6 bromide)
2-(5-Bromo-2-methylphenyl)-5-(4-fluorophenyl)thiophene
2-(4-Fluorobenzene)-5-(5-bromo-2-methylbenzyl)thiophene
2-(2-Methyl-5-bromobenzyl)-5-(4-fluorobenzene)thiophene
2-(5-Bromo-2-methylbenzyl)-5-(4-fluorophenyl)thiophene
2-(5-Bromo-2-methylphenyl)methyl)-5-(4-fluorophenyl)thiophene
2-(4-Fluorophenyl)-5-[(5-bromo-2-methylphenyl)methyl]thiophene
2-(5-Bromo-2-methyl-benzyl)-5-(4-fluoro-phenyl)-thiophene
2-(4-Fluorophenyl)-5-((5-bromo-2-methylphenyl)methyl)thiophene
2-((5-bromo-2-methylphenyl)methyl)-5-(4-fluorophenyl)thiophene
2-[(5-bromo-2-methylphenyl)methyl]-5-(4-fluorophenyl)thiophene
English name: 2-((5-bromo-2-methylphenyl)methyl)-5-(4-fluorophenyl)thiophene
English name: Canogliflozin
Canagliflozin INT4
Canagliflozin Intermediate2
Canagliflozin Intermediate  II
2-(5-bromo-2-methyl-benzyl-(5-fluorophenyl)thiophene
2-(5-Bromo-2-Methylbenzyl)-5-(4-fluorophenyl)thiophene
2-(5-BroMo-2-Methylbenzyl)-5-(4-fluorophenyl)thiophene
2-((5-bromo-2-methylphenyl)methyl)-5-(4-fluorophenyl)thiophene
2-[(5-Bromo-2-methylphenyl)methyl]-5-(4-fluorophenyl)thiophene
2-[(5-Bromo-2-Methylphenyl)Methyl]-5-(4-Fluorophenyl)Thiophene
Thiophene, 2-[(5-bromo-2-methylphenyl)methyl]-5-(4-fluorophenyl)-
Thiophene, 2-[(5-broMo-2-Methylphenyl)Methyl]-5-(4-fluorophenyl)-
CAS registration number: 1030825-20-7
EINECS number: 807-103-7
Molecular formula: C18H14BrFS
Molecular weight: 361.27

Physical and chemical properties:
Appearance: light yellow to white powder
Melting point: 103 °C
Boiling point: 438.3±40.0 °C (Predicted)
Relative density (water = 1): 1.388

Quality indicators:
Appearance: light yellow to white powder
Assay: ≥98%

Additional Information:
Packaging and storage: sealed storage, stored in a cool, dry warehouse.
Uses: APIs canagliflozin/canagliflozin intermediate for the treatment of adult patients with type II diabetes.